Literature DB >> 11591856

Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.

G Schifitto1, C Yiannoutsos, D M Simpson, B T Adornato, E J Singer, H Hollander, C M Marra, M Rubin, B A Cohen, T Tucker, I J Koralnik, D Katzenstein, B Haidich, M E Smith, S Shriver, L Millar, D B Clifford, J C McArthur.   

Abstract

HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591856     DOI: 10.1212/wnl.57.7.1313

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction.

Authors:  Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Schwann cells as a therapeutic target for peripheral neuropathies.

Authors:  Helmar C Lehmann; Ahmet Höke
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

3.  Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation.

Authors:  Amanda Peltier; A Gordon Smith; James W Russell; Kiran Sheikh; Billie Bixby; James Howard; Jonathan Goldstein; Yanna Song; Lily Wang; Eva L Feldman; J Robinson Singleton
Journal:  Muscle Nerve       Date:  2009-04       Impact factor: 3.217

Review 4.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 5.  Growth factors and neuropathic pain.

Authors:  Michael H Ossipov
Journal:  Curr Pain Headache Rep       Date:  2011-06

6.  Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling.

Authors:  Kristian L Hedstrom; Joshua C Murtie; Kathryn Albers; Nigel A Calcutt; Gabriel Corfas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

Review 7.  Update of HIV-Associated Sensory Neuropathies.

Authors:  Angela Aziz-Donnelly; Taylor B Harrison
Journal:  Curr Treat Options Neurol       Date:  2017-08-31       Impact factor: 3.598

Review 8.  Neuromuscular diseases associated with HIV-1 infection.

Authors:  Jessica Robinson-Papp; David M Simpson
Journal:  Muscle Nerve       Date:  2009-12       Impact factor: 3.217

Review 9.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.